基于日本某市疫苗接种登记链接的行政索赔数据对COVID-19 mRNA疫苗接种后严重不良结局的上市后安全性评估
该研究利用日本某市2020年9月至2021年9月的行政索赔数据库链接COVID-19疫苗接种登记,纳入184491名≥18岁参保人,采用队列研究和改良自控病例系列(SCCS)评估接种后21天内严重不良结局风险。结果显示除女性首剂后肺栓塞风险信号外,各结局风险均未增加。
要点
- 研究纳入184491名参保人,其中男性87218名,平均年龄64.2岁。
- 队列研究和改良SCCS分析中,除女性首剂后肺栓塞外,所有结局风险均未增加。
- 改良SCCS显示女性首剂后肺栓塞风险升高,组内IRR为3.97(95%CI 1.18-13.32)。
核心结论
- 研究结果提示COVID-19 mRNA疫苗总体安全,但观察到首剂接种后肺栓塞的信号。
研究设计与样本
- 利用日本某市2020年9月至2021年9月行政索赔数据库链接COVID-19疫苗接种登记,识别≥18岁健康保险参保人,开展队列研究和改良自控病例系列(SCCS)分析。
- 队列研究采用Poisson回归估计发病率比(IRR),加权最小二乘回归估计率差(IRD),调整性别、年龄和Charlson合并症指数。
- 改良SCCS采用加权条件Poisson回归估计组内IRR,并按性别和年龄进行亚组分析。
主要发现
- 共识别184491名参保人,其中男性87218名,平均(标准差)年龄64.2(19.5)岁,首剂接种136667人,第二剂接种127322人。
- 除女性首剂后肺栓塞外,任何分析中任何结局的风险均未增加。
- 改良SCCS显示女性首剂后肺栓塞风险升高,组内IRR为3.97(95%CI 1.18-13.32)。
关键数值与推荐
- 评估的结局包括急性心肌梗死、阑尾炎、贝尔麻痹、惊厥/癫痫发作、弥散性血管内凝血、免疫性血小板减少症、肺栓塞、出血性或缺血性卒中、静脉血栓栓塞症和全因死亡,观察期为任何COVID-19 mRNA疫苗接种后21天,与非接种期比较。
- 亚组分析按性别和年龄分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The safety profiles of COVID-19 vaccines are incompletely evaluated in Japan. OBJECTIVES: To examine the risk of serious adverse effects after COVID-19 mRNA vaccination (BNT162b2 and mRNA-1273) in cohort studies and self-controlled case series (SCCS). METHODS: Using an administrative claims database linked with the COVID-19 vaccination registry in a city in Japan between September 2020 and September 2021, we identified health insurance enrolees aged ≥ 18 years. We evaluated the risk of acute myocardial infarction, appendicitis, Bell's palsy, convulsions/seizures, disseminated intravascular coagulation, immune thrombocytopenia, pulmonary embolism, haemorrhagic or ischemic stroke, venous thromboembolism, and all-cause mortality, 21 days following any COVID-19 mRNA vaccination, compared with non-vaccination periods. For the cohort studies, we estimated incidence rate ratios (IRRs) by Poisson regression and rate differences (IRDs) by weighted least-squares regression, adjusting for sex, age, and Charlson comorbidity index. We applied a modified SCCS design to appropriately treat outcome-dependent exposures. For the modified SCCS, we estimated within-subject IRRs by weighted conditional Poisson regression. Subgroup analyses stratified by sex and age were also conducted. RESULTS: We identified 184,491 enrolees [male: 87,218; mean (standard deviation) age: 64.2 (19.5) years] with 136,667 first and 127,322 s dose vaccinations. The risks of any outcomes did not increase in any analyses, except for the fact that the modified SCCS indicated an increased risk of pulmonary embolism after the first dose in women (within-subject IRR [95%CI]: 3.97 [1.18-13.32]). CONCLUSION: The findings suggested that the COVID-19 mRNA vaccine was generally safe, whilst a signal of pulmonary embolism following the first dose of the COVID-19 mRNA vaccine was observed.
引用
- Takeuchi Y, Iwagami M, Ono S, et al. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. Vaccine. 2022. PMID: 36371366. doi:10.1016/j.vaccine.2022.10.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。